Cornea

Latest News

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

July 21st 2025

The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.

OKYO Pharma receives $1.9 million in non-dilutive funding
OKYO Pharma receives $1.9 million in non-dilutive funding

July 21st 2025

Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula
Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula

July 21st 2025

Lupin launches loteprednol etabonate ophthalmic suspension, 0.5%, in the United States
Lupin launches loteprednol etabonate ophthalmic suspension, 0.5%, in the United States

July 19th 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain

July 18th 2025

Video Interviews
Podcasts
3 Things You Should Know About the GA Pipeline
Patient-Centered Treatment Strategies in the Management of nAMD and DME
3 Things You Should Know About Early Treatment Intervention for TED
3 Things You Should Know About the GA Pipeline
The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Latest CME Events & Activities

Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)

View More

Retina Specialists: Join us in Long Beach

July 31, 2025 - August 2, 2025

Register Now!

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

August 27, 2025

View More

SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application

View More

Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

View More

3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between

September 6, 2025

Register Now!

Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease

View More

Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D

View More

EyeCon 2025

September 26-27, 2025

Register Now!

Optometrists: Earn COPE CE Credits in Portland or Virtually

October 16-17, 2025

Register Now!

Join us at The Ophthalmology Meeting in Orlando this October

October 18, 2025

Register Now!

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)

View More

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

View More

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Expert Perspectives on Technological Advances in Cataract Surgery

View More

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

View More

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

View More

(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

View More

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

View More

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

View More

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

View More

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

View More

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

View More

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

View More

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

View More

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

View More

More News

© 2025 MJH Life Sciences

All rights reserved.